Due to the ongoing global pandemic Covid-19, ESO and ESMO have taken the decision to convert the 6th ESO-ESMO Latin-American Masterclass in Clinical Oncology that was scheduled in 21-25 April 2021, into virtual ON-LINE MASTERCLASSES.
We have done our best to design and build a new programme keeping the interactive, international, and collaborative Masterclass spirit which will include prerecorded lectures, live sessions, clinical case presentations and direct contact with the Faculty members.
Programme, dates and further info will be available soon.
The online edition will be divided into two parts:
Pre-recorded lectures will be organized into Modules based on tumour type and made available for participants to view in their own time one month before part 2. On completion of each module, participants will be given the opportunity to send questions related to the lectures, that will then be answered Live by the Faculty during part 2.
All modules from part 1 must be completed before part 2.
Online live event with lectures/ live discussion and participants’ case presentations.
MCO Coordinator: N. Pavlidis, GR
ESO Chair: F. Peccatori, IT
ESMO Chair: S. Peters, CH
Host Chair: M. Chacon, AR
Scientific Advisors: F. Cardoso, PT - A. Cervantes, ES - F. Lordick DE - R. Stahel, CH
The Masterclass is the most structured ESO educational activity whose format has been established and presented in Europe for over a decade. The success of the teaching method has been confirmed by the events held also in other parts of the world as well as by the five editions held in Latin America. The Masterclass offers plenary lectures discussing current issues and controversies as well as critically reviewing significant therapeutic developments. State-of-the-art data recognized by ESMO and other evidence-based guidelines will be cited. Spotlight sessions will facilitate compact update on different topics related to cancer care.
The clinical sessions will be complemented by tumour board discussions supported by regional tutors.
Participants will deliver case presentations within small tumour board groups and discuss these with the experts.
As for all Masterclasses, the number of participants will be limited and admission will be by competitive application only.
The Masterclass will be entirely in English and at least an intermediate level of English is necessary for admission.
In preparation of the attendance, participants will be requested to follow four selected e-ESO sessions (www.e-eso.net).
• Improve medical oncologists’ skills
• Practicing case discussion
• Deep focus on breast, gastro-intestinal, genitourinary, gynaecological and lung cancers
• Compact update on further topics of interest
• Breast cancer
• Gastro-intestinal cancers
• Genito-urinary cancers
• Gynaecological cancers
• Lung cancer
Clinical Oncology is an
ESO-ESMO joint event
|In collaboration with|
|Under the auspices of|
|Communication skills workshop organised by
In this review, the authors summarize the history of the 41 Masterclasses in Clinical Oncology (MCO) organized by ESO or ESO-ESMO during the last 17 years. The MCO has become a major educational event of ESO, intending to educate young oncologists from various countries within or outside Europe, providing an up-to-date interactive program based on solid evidence for all presented topics.
"Reprinted from Critical Reviews in Oncology / Hematology, Pavlidis et al, Copyright (2019)
https://doi.org/10.1016/j.critrevonc.2019.07.022 with permission from Elsevier”
• Download PDF document
The complete list of invited speakers will soon be updated.
European School of Oncology
Piazza Indipendeza 2, 6500 Bellinzona, Switzerland
Laura Richetti, Ph +41 91 820 09 51, E-mail: email@example.com
The Masterclass will be held in English and translation will not be provided.
Application for CME recognition will be submitted to the European Society for Medical Oncology (ESMO) for ESMO-MORA accreditation, to the Accreditation Council of Oncology in Europe (ACOE), The American Medical Association (AMA) and the Accreditation Council for Continuous Medical Education (ACCME).
Being selected to take part in an ESO Masterclass is one of the ESO activities that gives participants eligibility to enrol in ESCO - the College of the European School of Oncology.
A Masterclass also enables ESCO students to earn ESCO credits and therefore access more ESCO benefits. Full and active participation in the Masterclass earns participants 30 ESCO credits.
Visit www.esco.org for information on how to join ESCO.
In the event of registrations to events held in partnership with other entities (clearly specified in the title of the event or by sending a request to ESO), please be aware that the partner should be considered joint data controller and that the consents provided to ESO will be transferred to the partner as well. Any subsequent consent modifications will need to be communicated to the partner directly.
PARTICIPANT’S PROFILE OF THE MASTERCLASS CANDIDATE
• Age between 30 and 40 years
• At least 2-3 years’ experience in medical oncology
• Involvement in scientific activities (desirable)
•- At least an intermediate level of English language (simple scientific discussion in English)
• Practicing in Latin-America
ATTENDANCE TO THE MASTERCLASS IS BY APPLICATION ONLY
Successful applicants are granted free registration
THE APPLICATION DEADLINE HAS PASSED (17 JANUARY 2021)
The ONLINE 6th ESO-ESMO Latin-American Masterclass in Clinical Oncology will be divided into 2 parts:
Pre-recorded lectures will be made available to selected participants from 24th March 2021
Part 1 will be divided into 6 blocks, one for each tumour type and one including topics of general interest. Each block can be viewed in your own time, but all blocks must be viewed before Part 2.
A full detailed programme of Part 1 can be found below.
All participants will be asked to send up to 3 questions, each related to a big killer: the questions will be answered during part 2.
PART 2: (Dates: 24-25 April 2021)
Online live event with lectures on latest updates or specifically related to the region, live discussions (Q&A) and participants’ case presentations in tumour boards.
Details of Part 2 will soon be published.
Part 1 Programme:
Part 1 has 6 blocks:
Block 1) Breast cancer
- Current controversies and challenges in breast cancer surgery – MJ Cardoso, PT
- Systemic treatment of early and advanced triple negative disease – G. Curigliano, IT
- Systemic treatment of HER2+ early and advanced disease – A. Eniu, CH
- Current controversies and challenges in radiotherapy – F. Geara, LB
- Preoperative chemotherapy and biologicals – N. Harbeck, DE
- Systemic treatment of luminal early and advanced breast cancer – O. Pagani, CH
- Molecular diagnostic pathology – G. Pruneri, IT
- Optimal approach in locally advanced disease: ESO-ESMO ABC Guidelines – F. Cardoso, PT
Block 2) Lung cancer
- Multimodality treatment of stage III NSCLC – R. Dziadziuszko, PL
- Molecular diagnostic pathology of NSCLC – I. Kern, SI
- Radiotherapy for NSCLC – F. Mc Donald, UK
- Systemic therapy for NSCLC with oncogenic driver mutations – C. Rolfo, US
- Systemic therapy for NSCLC without oncogenic driver mutations – S. Peters, CH
- Multimodality treatment of SCLC – R. Stahel, CH
- Surgery for early and locally advanced NSCLC – I. Schmitt-Opitz, CH
Block 3) Gastro-intestinal cancer
- Multimodal management of localized rectal cancer – A. Cervantes, ES
- Management of pancreatic cancer – S. De Dosso, CH
- Systemic treatment in advanced oesophageal and gastric cancer – F. Lordick, DE
- Adjuvant treatment in colon cancer – D. Papamichael, CY
- Liquid biopsies in GI tumors – F. Penault-Llorca, FR
- Optimal sequencing of systemic treatment for advanced hepatocellular carcinoma – A. Vogel, DE
- Systemic treatment in advanced colorectal cancer – E. van Cutsem, BE
Block 4) Gynaecological cancer
- Management of endometrial/cervical cancers – C. Sessa, CH
- Systemic management of ovarian cancer and inhibitors of Parp – J.B. Vermorken, BE
- New ESMO guidelines in Endometrial cancer – N. Colombo, IT
Block 5) Genitourinary cancer
- Management of testicular cancer – J. Beyer, CH
- First line endocrine therapy in endocrine sensitive prostate cancer – K. Fizazi, FR
- Localized prostate cancer – J. Khader, JO
- Systemic treatment of bladder cancer – H. Khaled, EG
- Treatment of endocrine resistant and refractory prostate cancer – X. Maldonado, ES
- Metastatic renal cancer: evidence-based treatment – N. Mottet, FR
Block 6) Spotlights
- Communication skills – F. Boyle, AU
- Ethics issues – S. Hurst-Majno, CH
- Breast cancer during pregnancy and fertility preservation – F.A. Peccatori, IT
- Early integration in oncology, supportive and palliative care – S. Peters, CH
- Cancer patients with COVID-19 – M. Garassino, IT
- Nutrition – J. Arends, DE
- Genomic Tests in clinical practice – F. Cardoso, PT
- Cancer in the elderly – M. Aapro, CH
- Immuno-oncology – H.A. Azim Jr., MX